Fierce Biotech August 28, 2024
Gabrielle Masson

Flagship Pioneering and Pfizer have added Quotient into their 10-program partnership, inking a deal to discover new targets for two programs in cardiovascular and renal diseases.

The deal fits into a larger equation: Back in July 2023, Pfizer and Flagship Pioneering each put down $50 million to build a 10-program pipeline. The Big Pharma said the VC firm and its bioplatform companies could make up to $700 million in biobucks for each successful drug that emerges from the pact.

Now, Flagship-founded Quotient will work with Flagship’s drug development arm—dubbed Pioneering Medicines—to spot somatic mutations in genes that change the progression of heart and kidney diseases, according to an Aug. 28 release.

“Quotient’s somatic genomics platform explores the extensive genetic...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Partnerships, Pharma, Pharma / Biotech, Trends
Pharma Pulse 3/14/25: Navigating Internal Constraints and Uncertainty, Health Plan Support During Natural Disasters & more
New AI model can estimate a person's true biological age from five drops of blood
Spotiphy AI Tool Enhances Spatial Transcriptomics for Precision Medicine
Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal
FDA Approves First Biosimilar to Omalizumab

Share This Article